[AKBA] Akebia Therapeutics, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 325.49 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 10.6 Change: 0.51 (5.05%)
Ext. hours: Change: 0 (0%)

chart AKBA

Refresh chart

Description: Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. Its lead product candidate is AKB-6548, a HIF-PH inhibitor, which is in Phase IIb clinical trials for patients with anemia secondary to chronic kidney disease who are not dependent on dialysis. The company is also developing a development program for patients dependent on dialysis. Akebia Therapeutics, Inc. was founded in 2007 and is headquartered in Cambridge, Massachusetts.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding37.98 M EPS-4.05 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-3.48
P/E To EPS Growth P/S P/BV3.44 Price/Cash Per Share3.24
Price/Free Cash Flow ROA-36.76% ROE-40.2% ROI
Current Ratio11.62 Quick Ratio Long Term Debt/Equity Debt Ratio0.09
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities50 K Cash From Investing Activities3.4 M Cash From Operating Activities-8.35 M Gross Profit
Net Profit-10.7 M Operating Profit-10.79 M Total Assets103.46 M Total Current Assets102.69 M
Total Current Liabilities8.84 M Total Debt Total Liabilities8.85 M Total Revenue
Technical Data
High 52 week18.15 Low 52 week5.39 Last close6.18 Last change0.65%
RSI54.95 Average true range0.43 Beta1.18 Volume394.84 K
Simple moving average 20 days3.15% Simple moving average 50 days-14.05% Simple moving average 200 days-36.77%
Performance Data
Performance Week-4.92% Performance Month-19% Performance Quart-28.22% Performance Half-35.02%
Performance Year-65.08% Performance Year-to-date11.75% Volatility daily4.97% Volatility weekly11.12%
Volatility monthly22.79% Volatility yearly78.95% Relative Volume2357.44% Average Volume1.01 M
New High New Low

News

2020-06-02 16:30:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-05-26 08:00:00 | Akebia Therapeutics to Present at Jefferies Virtual Global Healthcare Conference

2020-05-21 16:05:00 | Akebia Therapeutics Announces Change to Virtual Annual Meeting of Stockholders

2020-05-19 16:05:00 | Akebia Therapeutics Announces Full Exercise of Underwriters' Option to Purchase Additional Shares

2020-05-18 08:00:00 | Akebia Therapeutics Announces Collaboration Partner's Submission of Supplemental New Drug Application for Use of Riona® ferric citrate hydrate to Treat Adult Patients with Iron Deficiency Anemia in Japan

2020-05-13 11:37:03 | Akebia Therapeutics, Inc. AKBA Shares March Higher, Can It Continue?

2020-05-11 21:15:00 | Akebia Therapeutics Announces Pricing of Upsized Public Offering of Common Stock

2020-05-11 16:01:00 | Akebia Therapeutics Announces Proposed Public Offering of Common Stock

2020-05-11 08:36:12 | How Akebia Therapeutics AKBA Stock Stands Out in a Strong Industry

2020-05-08 18:28:27 | Edited Transcript of AKBA earnings conference call or presentation 5-May-20 12:30pm GMT

2020-05-08 08:00:00 | Akebia Therapeutics to Present at RBC Capital Markets Global Healthcare Virtual Conference

2020-05-07 14:15:46 | US$17.13 - That's What Analysts Think Akebia Therapeutics, Inc. NASDAQ:AKBA Is Worth After These Results

2020-05-07 11:24:25 | Akebia Shares Climb on Positive Anemia Drug Study Results

2020-05-06 01:49:49 | Akebia Spikes 38% On Pivotal Trial Readout; And Further Upside Lies Ahead

2020-05-05 18:00:48 | Akebia Therapeutics Inc AKBA Q1 2020 Earnings Call Transcript

2020-05-05 11:50:00 | Why Akebia Therapeutics Stock Is Crushing It Today

2020-05-05 09:45:01 | Akebia Therapeutics AKBA Reports Q1 Loss, Tops Revenue Estimates

2020-05-05 09:38:16 | Recap: Akebia Therapeutics Q1 Earnings

2020-05-05 07:30:00 | Akebia Announced Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis; Reports First Quarter 2020 Financial Results

2020-05-05 07:21:00 | Akebia's shares jump on late-stage clinical trial results for kidney disease drug

2020-05-05 07:21:00 | Akebia's shares jump on late-stage clinical trial results for kidney disease drug

2020-05-04 16:30:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-04-28 08:00:00 | Akebia Therapeutics to Report First Quarter 2020 Financial Results and Discuss Recent Business Highlights

2020-04-17 06:44:42 | Does Akebia Therapeutics NASDAQ:AKBA Have A Healthy Balance Sheet?

2020-04-14 16:41:53 | Seth Klarman Dials Down Akebia Therapeutics Stake

2020-04-10 18:31:17 | INVESTOR ALERT: Fields Kupka & Shukurov LLP Is Investigating Akebia Therapeutics, Inc. for Potential Breach of Fiduciary Duty Claims.

2020-04-07 08:00:00 | Akebia Therapeutics Appoints Myles Wolf, M.D., M.M.Sc., Chief of Nephrology and Professor at Duke University School of Medicine, to Board of Directors

2020-04-02 16:30:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-04-02 10:00:02 | Is the Options Market Predicting a Spike in Akebia Therapeutics AKBA Stock?

2020-03-26 18:36:36 | Edited Transcript of AKBA earnings conference call or presentation 10-Mar-20 1:00pm GMT

2020-03-23 08:00:00 | Akebia Therapeutics to Present Research at NKF 2020 Spring Clinical Meetings Live Virtual Conference

2020-03-15 21:28:00 | A Message from Akebia Therapeutics, Inc.’s Chief Executive Officer to Our Patients, Healthcare Providers, and Other Stakeholders During the Rapidly Evolving COVID-19 Pandemic:

2020-03-12 06:20:33 | Akebia Therapeutics, Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates

2020-03-10 09:15:01 | Akebia Therapeutics AKBA Reports Q4 Loss, Misses Revenue Estimates

2020-03-10 07:49:00 | Akebia Therapeutics Reports Fourth Quarter and Full-Year 2019 Financial Results and Hosts Conference Call to Discuss Recent Business Highlights

2020-03-10 07:00:00 | Akebia Therapeutics, Inc. to Host Earnings Call

2020-03-03 12:30:05 | Will Akebia Therapeutics AKBA Report Negative Earnings Next Week? What You Should Know

2020-03-02 16:05:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-03-01 07:04:02 | One Thing To Remember About The Akebia Therapeutics, Inc. NASDAQ:AKBA Share Price

2020-02-25 09:41:02 | Is the Options Market Predicting a Spike in Akebia Therapeutics AKBA Stock?

2020-02-24 08:00:00 | Akebia Therapeutics to Report Fourth Quarter and Full-Year 2019 Financial Results and Discuss Recent Business Highlights

2020-02-04 16:05:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-01-31 07:10:59 | Akebia Therapeutics, Inc. NASDAQ:AKBA Insiders Increased Their Holdings

2020-01-06 08:00:00 | Akebia Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare Conference

2020-01-03 16:05:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2020-01-01 05:14:59 | Analysts Expect Breakeven For Akebia Therapeutics, Inc. NASDAQ:AKBA

2019-12-11 13:57:49 | Did Hedge Funds Drop The Ball On Akebia Therapeutics Inc AKBA ?

2019-12-10 12:22:22 | Seth Klarman Pares Paratek Pharmaceuticals Stake

2019-12-03 16:06:00 | Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635c4

2019-12-02 08:57:01 | Options Traders Expect Huge Moves in Akebia Therapeutics AKBA Stock